{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:50:02Z","timestamp":1760028602501},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T00:00:00Z","timestamp":1242086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Investigation"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background\u2002<\/jats:bold> High concentrations of high density lipoprotein\u2010cholesterol (HDL\u2010c) are associated with lower cardiovascular risk, but it is not known whether this is also the case in the presence of intensive low density lipoprotein\u2010cholesterol (LDL\u2010C) therapy. In this study, we determined the relationship between HDL\u2010c and new non\u2010fatal or fatal vascular events in patients with various manifestations of clinical evident vascular disease and evaluated whether this relationship is modified by LDL\u2010c levels.<\/jats:p><jats:p><jats:bold>Materials and methods\u2002<\/jats:bold> Prospective single centre, cohort study of 3837 patients with a history or recent diagnosis of clinical manifest vascular disease (coronary, cerebrovascular, peripheral arterial disease or abdominal aortic aneurysm) The relationship between HDL\u2010c quintiles and time to a new event (myocardial infarction, ischaemic stroke, vascular death) was quantified with Cox\u2010regression models and adjusted for potential confounders (age, gender, body mass index, type 2 diabetes, triglycerides, smoking, use of alcohol and lipid\u2010lowering therapy). Effect modification of LDL\u2010c was assessed with interaction terms.<\/jats:p><jats:p><jats:bold>Results\u2002<\/jats:bold> During a median follow up of 3\u00b73 (range 0\u00b71\u20139\u00b75) years, a total of 465 first new events occurred. Compared with the lowest quintile, the upper quintile of HDL\u2010c levels was associated with a lower risk for new events; Hazard Ratio 0\u00b761 (95% CI 0\u00b743\u20130\u00b786) irrespective of the localisation of vascular disease and use of lipid\u2010lowering medication. Higher HDL\u2010c levels were associated with comparably lower risks for vascular events in patients with LDL\u2010c levels above and below 2\u00b75\u2003mmol\u2003L<jats:sup>\u22121<\/jats:sup> (<jats:italic>P<\/jats:italic>\u2010values for interaction &gt;\u20030\u00b705).<\/jats:p><jats:p><jats:bold>Conclusions\u2002<\/jats:bold> Patients with various clinical manifestations of vascular diseases in the highest HDL\u2010c quintile have a lower risk for vascular events compared with patients in the lowest HDL\u2010c quintile. Further, the current results expand the evidence by showing that also in a cohort of patients with various localisations of clinical evident vascular disease, in which statins were widely used, higher HDL\u2010c levels confer a lower risk for developing new vascular events, irrespective of the localisation of vascular disease, use of lipid\u2010lowering medication and plasma LDL\u2010c concentration.<\/jats:p>","DOI":"10.1111\/j.1365-2362.2009.02155.x","type":"journal-article","created":{"date-parts":[[2009,5,12]],"date-time":"2009-05-12T05:26:35Z","timestamp":1242105995000},"page":"680-688","source":"Crossref","is-referenced-by-count":10,"title":["Low plasma HDL\u2010c, a vascular risk factor in high risk patients independent of LDL\u2010c"],"prefix":"10.1111","volume":"39","author":[{"given":"G. R.","family":"Hajer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Van Der Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. L.","family":"Bots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Algra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. L. J.","family":"Visseren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the SMART Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,7,3]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199006143222403"},{"key":"e_1_2_8_3_2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","author":"Scandinavian Simvastatin Survival Study Group","year":"1994","journal-title":"Lancet"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199610033351401"},{"key":"e_1_2_8_5_2","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/S0195-668X(03)00347-6","article-title":"Third joint task force of european and other societies on cardiovascular disease prevention in clinical practice","volume":"24","author":"European guidelines on cardiovascular disease prevention in clinical practice","year":"2003","journal-title":"Eur Heart J"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.07.001"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000170946.56981.5c"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp044370"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa071359"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00489-0"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(01)00651-7"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9150(96)05852-2"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.8.6.737"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a060331"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00395-9"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00035-9"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa070635"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61088-5"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007621514757"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/18.6.499"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2481"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.16.8.963"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90874-9"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.31.8.1882"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000183727.90611.4f"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67663-5"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.21.2709"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00737.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198711123172001"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199908053410604"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00703-7"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(94)90546-0"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000256728.60226.77"},{"key":"e_1_2_8_37_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0022-2275(20)39891-6","article-title":"High density lipoprotein subfractions in non\u2010insulin\u2010dependent diabetes mellitus and coronary artery disease","volume":"36","author":"Syvanne M","year":"1995","journal-title":"J Lipid Res"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-004-1655-5"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa064278"}],"container-title":["European Journal of Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2362.2009.02155.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2362.2009.02155.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T17:31:49Z","timestamp":1697218309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2362.2009.02155.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,3]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1365-2362.2009.02155.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2362.2009.02155.x","archive":["Portico"],"relation":{},"ISSN":["0014-2972","1365-2362"],"issn-type":[{"type":"print","value":"0014-2972"},{"type":"electronic","value":"1365-2362"}],"subject":[],"published":{"date-parts":[[2009,7,3]]}}}